Shane Johnson Biography and Net Worth



Dr. Shane Johnson’s career has focused principally on offering strategic business advisory services to companies in the biotechnology and healthcare sectors. His work has included guiding regulatory strategy, product portfolio assessment and valuations, and product development and launch strategies for companies including Biogen Idec, Amgen, and Genentech.

Shane was a Principal at Hamilton BioVentures (a Life Science venture capital firm), an Engagement Manager at L.E.K. Consulting (an international strategy consulting firm), and held operational roles in several early stage companies. For the past 4 years, Shane’s work has been focused on the cannabis and cannabinoid science space,

How do I contact Shane Aaron Johnson?

The corporate mailing address for Dr. Johnson and other InMed Pharmaceuticals executives is , , . InMed Pharmaceuticals can also be reached via phone at 604-669-7207 and via email at [email protected]. Learn More on Shane Aaron Johnson's contact information.

Has Shane Aaron Johnson been buying or selling shares of InMed Pharmaceuticals?

Shane Aaron Johnson has not been actively trading shares of InMed Pharmaceuticals during the last quarter. Most recently, on Thursday, January 6th, Shane Aaron Johnson bought 8,500 shares of InMed Pharmaceuticals stock. The stock was acquired at an average cost of $1.26 per share, with a total value of $10,710.00. Learn More on Shane Aaron Johnson's trading history.

Who are InMed Pharmaceuticals' active insiders?

InMed Pharmaceuticals' insider roster includes Eric Adams (CEO), Bruce Colwill (CFO), and Shane Johnson (SVP). Learn More on InMed Pharmaceuticals' active insiders.

Are insiders buying or selling shares of InMed Pharmaceuticals?

During the last twelve months, InMed Pharmaceuticals insiders bought shares 2 times. They purchased a total of 79,100 shares worth more than $29,601.00. The most recent insider tranaction occured on February, 21st when Director Andrew Hull bought 37,500 shares worth more than $14,625.00. Insiders at InMed Pharmaceuticals own 1.4% of the company. Learn More about insider trades at InMed Pharmaceuticals.

Information on this page was last updated on 2/21/2024.

Shane Aaron Johnson Insider Trading History at InMed Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/6/2022Buy8,500$1.26$10,710.00View SEC Filing Icon  
12/30/2021Buy8,093$1.33$10,763.69View SEC Filing Icon  
11/15/2021Buy5,000$1.37$6,850.00View SEC Filing Icon  
See Full Table

Shane Aaron Johnson Buying and Selling Activity at InMed Pharmaceuticals

This chart shows Shane Aaron Johnson's buying and selling at InMed Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

InMed Pharmaceuticals Company Overview

InMed Pharmaceuticals logo
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $0.33
Low: $0.33
High: $0.36

50 Day Range

MA: $0.36
Low: $0.32
High: $0.44

2 Week Range

Now: $0.33
Low: $0.29
High: $2.08

Volume

58,060 shs

Average Volume

165,994 shs

Market Capitalization

$2.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.11